Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription
Posted April 21, 2008
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
Analysis of: CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection | www.pipelinereview.com
Author: GLG Member Program Contributor
Regadenoson is similar to the drug it's set to replace, adenosine, in terms of its ability to increase coronary flow and detect coronary artery disease. However, it's easier to use (it's given as a bolus as opposed to an infusion over 3-5 minutes) and seems to have less side effects. It also has a longer...
Posted April 14, 2008
Study Suggests Antiretroviral HIV Drug Linked to Increased Risk of Heart Attack
Analysis of: Study Suggests Antiretroviral HIV Drug Linked to Increased Risk of Heart Attack | pharmalive.com
Author: GLG Member Program Contributor
This study should make practictioners more aware of potential side effects of the therapy for HIV. It is now a "chronic" disease and needs to be thought of in that way. Fortunately we have other drugs to use, but need to be on the lookout for long term side effects with them as well. What this teaches...
Posted April 7, 2008
Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study
Analysis of: Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study | www.pipelinereview.com
Author: GLG Member Program Contributor
Pfizer announced today that Lipitor® (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in myocardial ischemiaLipitor significantly reduced the average number of ischemic events by nearly 70 percent and total duration of events by more than 60 percent from baseline to week 18 of...
Posted April 4, 2008
Abbott's Phase III Studies of Investigational TriLipix (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
Analysis of: Abbott's Phase III Studies of Investigational TriLipix (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL | pharmalive.com
Author: GLG Member Program Contributor
Treating non LDL cholesterol is becoming more important. The more drugs we have the better. At some point we will be able to see which is better.
Posted April 4, 2008
Merck’s New Cholesterol Pill Has Mixed Results
Analysis of: Merck’s New Cholesterol Pill Has Mixed Results | www.pharmalot.com
Author: GLG Member Program Contributor
Vytorin was/is good to lower LDL. We need meds to lower non LDL and raise HDL.  This med if it truly has fewer side effects may accomplish this.
Posted April 4, 2008
Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study
Analysis of: Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study | www.pipelinereview.com
Author: GLG Member Program Contributor
Lipitor is the only statin tested to reduce ischemic stroke. The new study also proved its role in reduce angina and MI
David Engler Posted April 4, 2008
Xyzal--Just overpriced Zyrtec
Analysis of: New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Author: David Engler, Physician The Allergy Clinic
 A bottle of 30 Generic Zyrtec can be purchased for $15.  No one is going to get Xyzal that inexpensively. There are no head to head studies showing Xyzal to be better than Zyrtec.  Even though Xyzal claims a 6% sedation rate compared to Zyrtec's 14% rate, it's not apples to apples. ...
Posted April 3, 2008
Merck’s New Cholesterol Pill Has Mixed Results
Analysis of: Merck’s New Cholesterol Pill Has Mixed Results | www.pharmalot.com
Author: GLG Member Program Contributor
The potential side effect of liver damage of the new cholesterol agent from Merck will definitely slow or even halt the FDA approval of the medication.
Posted April 3, 2008
The Clot Thickens: Lilly’s Prasugrel Performs Well
Analysis of: The Clot Thickens: Lilly’s Prasugrel Performs Well | www.pharmalot.com
Author: GLG Member Program Contributor
There is no question that prasugel is a good drug. Side effects are an issue. If approved, its use needs to be somewhat restricted.
Posted April 3, 2008
Discontinuation of Development of TAK-475, A Compound for Treatment of Hypercholesterolemia
Analysis of: Discontinuation of Development of TAK-475, A Compound for Treatment of Hypercholesterolemia | www.pipelinereview.com
Author: GLG Member Program Contributor
The decision by Takeda to halt development of TAK-475, is not surprising considering the problems faced now by companies trying to get regulatory approval for new lipid-lowering drugs. TAK-475 was not more potent, but was thought to have a better safety profile than statins. However, because the safety...
Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 356

GLG News: What Experts Think Is Important





Analytics